Pneumococcal vaccination in adults: Recommendations, trends, and prospects

Cleveland Clinic Journal of Medicine

Volumn 74, Issue 6, 2007, Pages 401-414

  Targonski, Paul V ^a,b   Poland, Gregory A ^a,b  

^a Mayo Vaccine Research Group   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250212173     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.74.6.401     Document Type: Review

References (79)

1. HCUPnet. Health Care Cost and Utilization Project. Agency for Healthcare Research and Quality, Rockville, Md. http://hcupnet.ahrq.gov. Accessed May 10, 2007.
2. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642-1650.
3. Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep 2004; 52:1-47.
4. National Center for Health Statistics. Health, United States, 2003, with chartbook on trends in the health of Americans. Table 31. Leading causes of death and numbers of deaths, by sex, age, race and Hispanic origin: United States, 1980 and 2001. Hyattsville, MD: National Center for Health Statistics; 2003:144-147.
5. Centers for Disease Control and Prevention. Pneumococcal disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book, 9th ed. 2006:255-268. http://www.cdc.gov/nip/publications/ pink/pneumo.pdf. Accessed May 10, 2007.
6. Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1997; 46(RR-8):1-24.
7. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-229.
8. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-1735.
9. Active Bacterial Core surveillance website. http://www.cdc.gov/ ncidod/dbmd/abcs/survreports/spneu99.pdf. Accessed May 10, 2007.
10. US Department of Health and Human Services. Healthy People 2010: Understanding and improving health, 2nd ed. Washington, DC: US Department of Health and Human Services, 2000.
11. National Center for Health Statistics. Healthy People 2000 Final Review. Hyattsville, MD: Public Health Service, 2001:287.
12. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥ 65 years and persons 18-64 years with diabetes or asthma - United States, 2003. MMWR 2004, 53:1007-1012.
13. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93.
14. Henrichsen J. Six newly recognized types of Streptococcus pneumonia. J Clin Microbiol 1995; 33:2759-2762.
15. Butler JC. Shapiro ED, Carlone GM. Pneumococcal vaccines: history, current status, and future directions. Am J Med 1999; 107(1A):69S-76S.
16. Austrian R. Life with the pneumococcus: notes from the bedside, laboratory, and library. Philadelphia: University of Pennsylvania Press, 1985.
17. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-1159.
18. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine. J Infect Dis 1995; 171:885-890.
19. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270:1826-1831.
20. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines, 3rd ed. Philadelphia: WB Saunders Company, 1999:553-608.
21. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-1460.
22. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR 2000;49(No. RR-9).
23. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formation and use, Part I. Clin Infect Dis 2000; 30:100-121.
24. Jacobson RM, Poland GA. The pneumococcal conjugate vaccine. Minerva Pediatr 2002; 54:295-303.
25. Centers for Disease Control and Prevention. Notice to Readers: Pneumococcal vaccination for cochlear implant recipients. MMWR 2002; 51(41):931.
26. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 2000; 49(RR-10):1-128.
27. Advisory Committee on Immunization Practices. General recommendations on immunization. MMWR 2002; 51(RR02):1-36.
28. US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd edition. Baltimore: Williams and Williams, 1996.
29. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in the elderly and high-risk adults. Vaccine 2004; 22:927-946.
30. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22:3214-3224.
31. Loeb M, Stevenson KB, the SHEA Long-Term-Care Committee. Pneumococcal immunization in older adults: implications for the long-term-care setting. Infect Control Hosp Epidemiol 2004; 25:985-994.
32. Shorr AF. Preventing pneumonia: the role for pneumoccocal and influenza vaccines. Clin Chest Med 2005; 26:123-134.
33. Loeb M. Pneumonia in the elderly. Curr Opin Infect Dis 2004; 17:127-130.
34. Hedlund J, Stralin K, Ortqvist A. Holmberg H, and the Community-Aquired Pneumonia Working Group of the Swedish Society of Infectious Diseases. Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scand J Infect Dis 2005; 37:791-805.
35. DeGraeve D, Beutels P. Economic aspects of pneumococcal pneumonia. A review of the literature. Pharmacoeconom 2004; 22:719-740.
36. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19:353-363.
37. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004; 19:365-375.
38. Posfay-Barbe KM, Wald ER. Pneumococcal vaccines: do they prevent infection and how? Curr Opin Infect Dis 2004; 17:177-184.
39. Horwood F. Macfarlane J. Pneumococcal and influenza vaccination: current situation and future prospects. Thorax 2002; 57:24-30.
40. Whitney CG, Harper SA. Lower respiratory tract infections: prevention using vaccines. Infect Dis Clin North Am 2004; 18:899-917.
41. Zimmerman RK. If pneumonia is the "old man's friend," should it be prevented by vaccination? An ethical analysis. Vaccine 2005; 23:3843-3849.
42. Salo H, Sintonen H, Nuorti JP, et al. Economic evaluation of pneumococcal vaccination in Finland. Scand J Infect Dis 2005; 37:821-832.
43. Poland GA. The prevention of pneumococcal disease by vaccines: promises and challenges. Infect Dis Clin North Am 2001; 15:97-122.
44. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666-2677.
45. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-78.
46. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-4790.
47. Fate FT, Herzlich BC, Schiffman G, Ast AL. Impaired antibody responses to pneumococcal polysaccharide in elderly patients with low serum vitamin B12 levels. Ann Intern Med 1996; 124:299-304.
48. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83:425-430.
49. Jackson LA, Neuzil KM, Yu O, et al, for the Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755.
50. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093-1101.
51. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single blind population-based trial. Am J Med 1997; 103:281-290.
52. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study. N Engl J Med 1986; 315:1318-1327.
53. Ortqvist A. Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399-403.
54. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17:2493-2500.
55. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333-1339.
56. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653-657.
57. Fedson DS, Shapiro ED, LaForce FM, et al. Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med 1994; 154:2531-2535.
58. Vlasich C. Pneumococcal infection and vaccination in the elderly. Vaccine 2001; 19:2233-2237.
59. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 thorugh 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960-968.
60. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051.
61. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9.
62. Musher DM. Pneumococcal vaccine - direct and indirect ("herd") effects. N Engl J Med 2006; 354:1522-1524.
63. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930-938.
64. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1987-1494.
65. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.
66. Kyaw MH, Lynfield R, Schaffner W. et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-1463.
67. Poland GA. The burden of pneumococcal disease: the role of conjugate vaccines. Vaccine 1999; 17:1674-1679.
68. Boegart D, Hermans PW, Adrian PV, Rumke HC, deGroot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22:3890-3896.
69. Hollingshead SK, Baril L, Ferro S, et al. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol 2006; 55:215-221.
70. Kirkham LA, Kerr AR, Douce GR, et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 2006; 74:586-593.
71. Nuorti JR Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681-689.
72. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164:2206-2216.
73. Shefer A, McKibben L, Bardenheimer B, Bratzler D. Roberts H. Characteristics of long-term care facilities associated with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states. J Am Med Dir Assoc 2005; 6:97-104.
74. deHart MP, Salinas SK, Barnette LJ, et al. Project Protect: Pneumococcal vaccination in Washington state nursing homes. J Am Med Dir Assoc 2005; 6:91-96.
75. Dexter PR, Perkins SM, Maharry KS, Jones K, McDonald CJ. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates. A randomized trial. JAMA 2004; 292:2366-2371.
76. Lindenauer PK, Behal R, Murray CK, Nsa W, Houck PM, Bratzler DW. Volume, quality of care, and outcome in pneumonia. Ann Intern Med 2006; 144:262-269.
77. Centers for Disease Control and Prevention. Public health and aging: influenza vaccination coverage among adults aged ≥ 50 years and pneumococcal vaccination coverage among adults aged ≥ 65 years - United States, 2002. MMWR 2003; 52(41):987-992.
78. Nowalk MP, Zimmerman RK, Cleary SM, Bruehlman RD. Missed opportunities to vaccinate older adults in primary care. J Am Board Fam Pract 2005; 18:20-27.
79. Gardner P. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med 2003; 138:999-1000.